MTAP and metastatic prostate carcinoma: These MTAP deletions could be exploited as alternative therapy in MTAP-negative OS patients with the use of 6-thioguanine (6-TG), showing good results in leukemia or in metastatic prostate cancer models [121], or other inhibitors of de novo purine synthesis.